No Data
No Data
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
BMO Capital Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Raises Target Price to $61
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock
No Data
No Data
104476495 : h
104476495 : h
104247826 :
Malik ritduan : ok
大马周瑜 : ok
View more comments...